RZLT Company Profile and Key Details

RZLT has shown mixed momentum, gaining 15.14% over the past week and -66.74% over the past quarter, though year-to-date performance is up 22.46%. Short-term trend indicators are mixed aligned (SMA20 -0.94%, SMA50 15.71%, SMA200 -44.39%). The stock’s 14-day RSI is 48.09 (neutral), while the ATR of 0.34 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -71.28% below its high and over 207.48% above its low. Average 10-day trading volume of 1.40 million shares is below the 3-month average of 1.79 million, indicating normal recent market interest.

Rezolute, Inc. (NASDAQ:RZLT) closed at $4.91 USD, losing -$0.18 (-3.54%) from the previous close of $5.09. The stock is currently mid-range between its 52-week high and low $1.07 and $11.46. With a market capitalization of about $472.80 million, Rezolute, Inc. is classified as a small-cap and shows lower-than-market volatility (beta ~0.55). Key stats such as the average daily volume over the past year has been around 1.88 million shares, volume is running light vs its 52-week average. Headquartered in Redwood City, CA, Rezolute, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Nevan Charles Elam, the company employs approximately 71 people and listed since January 14, 2013. Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States.

Rezolute, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $1.22. This means the shares are trading above this model’s fair value.

Rezolute, Inc. has 87.00 million shares outstanding. The public float is 76.70 million shares, elevated short interest at 10.36% of float. This equals 7.42 million shares. The short ratio is 8.8 days. Institutional investors hold 100.83% of the float. Insiders own 10.15%. Genexine Inc. holds 91.30 million shares, Kim Young-Jin has 8.42 million shares and HANDOK, INC. has 5.94 million shares. Over the past six months, insider transactions show net buying. They sold 0.00 shares across 0 transactions.

Rezolute, Inc. generated EPS of -$0.92 over the past year. Five-year average earnings growth is 22.65%. Wall Street analysts project EPS growth of 18.27% annually over the next five years. The latest quarter delivered EPS of -$0.16. The next quarter is forecast at -$0.18. Next year's EPS is expected at $25.29. Analyst sentiment is bullish. Analyst rating data shows there are 4 Strong Buy ratings, 13 Buy ratings, 1 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $20.00 to $2.00. The high target offers 292.93% upside. The low target suggests -60.71% downside. The mean target is $11.33. This offers 122.59% upside. Rezolute, Inc. earnings surprise history is a mixed track record. The quarter that ended May 12, 2026, missed forecasts by -5.08%. The prior quarter beat by 37.5%. Over the last six quarters, Apple has recorded several small beats. These include -33.33% in February 12, 2025.

Rezolute, Inc. trades at a P/E ratio of -6.13, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 4.47 trading at moderately above to book value. The P/FCF stands at -6.58, also above market averages.

Our AI price prediction model suggests that Rezolute, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -4.32%, with price expected at $4.87 by August 04, 2026, within a range of $4.48 to $5.25 3-Month Outlook: Projected fall of -48.72%, reaching $2.61 by October 19, 2026, with a range of $1.40 to $2.82. 1-Year Outlook: Projected loss of -68.17%, with price at $1.62 by July 21, 2027, within a range of $0.00 to $0.00.

Rezolute, Inc. (NASDAQ:RZLT) shares are up 22.46% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Rezolute, Inc. trading at a premium to the broader market with a P/E of -6.13. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $12.35, suggesting 142.63% upside. Our AI forecast model points to short-term weakness (-4.32% over two weeks), a medium-term fall (-48.72% over three months), and a longer-term loss (-68.17% over one year), with expected trading ranges indicating moderate volatility.